Topic 22 · Everything else

3D Bioprinting & Future Technologies

Benchtop only. Nothing clinical, and nothing close.

→ Scientists are developing ways to 3D print cartilage and bone scaffolds custom-made for each patient's defect. Still experimental but represents the future of joint repair.

2025 Breakthrough: Hybrid 3D Bioprinting

Researchers from Singapore and Manchester developed a layered scaffold that mimics natural bone and cartilage structure [139]:

Key Technologies Under Development

Biphasic Scaffold Advances (2025)

PCL-based biphasic designs now offer [140]:

Status: Primarily laboratory research. Clinical translation ongoing. Represents promising future direction for complex OLT repair.

Added August 12, 2026 — a hyaline-cartilage cell therapy that names the ankle just finished its first human trial

→ The persistent failure of cartilage repair is that healing produces fibrocartilage — scar-like tissue — instead of the real thing. A Geneva group engineered mini-grafts of genuinely hyaline cartilage from the patient’s own cells, and their first-in-human safety trial, which explicitly included ankle lesions, is now complete.

The Cartibeads phase 1 trial (NCT06897098; Geneva University Hospitals, Hirslanden La Colline, EOC Lugano) was marked COMPLETED in an August 11, 2026 registry update [413]. Eleven adults with ICRS grade 3–4 focal lesions of 1.5–10 cm² received implanted 1–2 mm “Cartibead” mini-grafts — autologous chondrocytes expanded in culture, then pushed back into producing hyaline matrix by a patented maturation step before implantation. Two things separate this from the scaffold entries above: it reached humans, and the protocol includes the ankle by name — almost no cartilage cell-therapy trial does. What it is not: a treatment option. Eleven patients, safety-only endpoints, single-arm, Switzerland, and no results posted yet. The completed status starts the clock on a results publication — that publication, when it appears, is the thing worth reading.

Update, August 13, 2026 — the program has a company behind it, and an off-the-shelf sibling trial. The results-watch search turned up the other half of the picture: the lead sponsor of the Cartibeads trial is Vanarix SA, and the same sponsor has run a first-in-human trial of the allogeneic version — the same engineered hyaline mini-grafts, made from donor cells instead of the patient’s own — in 10 knee patients (NCT06897111, active, not recruiting, no results posted) [418]. That matters for the same reason the autologous trial did: every autologous cell therapy, MACI included, carries a two-stage harvest-then-implant cost. A donor-cell version that proves safe removes it. Both trials are Swiss, small, and unpublished — the watch item is unchanged: the results publication.

Added August 29, 2026 — a 3D-printed off-the-shelf cartilage implant is cleared for its first human trial

→ A US company called Nanochon got approval to start the first human trial of Chondrograft — a 3D-printed synthetic scaffold that replaces damaged cartilage, can bear weight immediately, and doesn’t require harvesting the patient’s own cells first. The trial is in the knee, and it will run in Panama.

This page’s scaffold entries have all been laboratory work; the cell-therapy entries above reached humans but carry the two-stage harvest-then-implant cost. An August 14 announcement puts a third class on the clinical clock [448]: Nanochon received approval from Panamá’s Ministry of Health (alongside an existing Health Canada clinical clearance) to begin the first-in-human study of Chondrograft™ — a 3D-printed porous nanocomposite implant for focal articular cartilage defects, designed to support immediate joint loading and recruit the patient’s own stem cells into hyaline-like regeneration, with no autologous cell harvest and no separate biopsy surgery. The trial runs at The Panama Clinic under a sports-medicine surgeon, in knees.

Discounts, all of them structural: a company press release, not a paper; knee-first, like every cartilage technology on this site; a first-in-human whose regulatory route runs through Panama rather than an FDA IDE, which is a speed choice that will eventually need US data anyway; and zero human outcomes today. Why it is carried: the treatment class — off-the-shelf, load-bearing immediately, single surgery — is precisely the profile that would matter for an active patient’s talus if it ever works, and this is the first entrant of that class to reach a human trial. Watch: a registry entry for the FIH study, and any stated ankle plans.

Update, September 1, 2026 — the registry entries existed all along, and both trials are already recruiting. The registration watch closes three days after it opened: a sponsor-scoped registry search found two Nanochon first-in-human early-feasibility studies, both RECRUITING — NCT07542184 at The Panama Clinic (5 patients, started July 30, 2026) and NCT07249489 in Canada (UBC Vancouver and a Toronto clinic, 10 patients, registered back in November 2025) [448]. Both are knee-only, ages 22–60, focal cartilage lesions, implanted by mini-arthrotomy or arthroscopy, with primary completions in late 2027. Fifteen patients across two countries is exactly what a first-in-human program should look like — small, safety-first, and years from an ankle. The watch item is now the interesting one: first human outcomes, and any ankle extension.